Q2 2026 saw 6% sales growth and revenue gains across all segments, though margins declined due to product mix and operational factors. Adjusted EPS fell 15% year-over-year, but strong demand in Pharma and Closures and ongoing innovation support a positive outlook for Q3.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.